Kenneth O’Byrne is a Professor of Medical Oncologist and Clinical Scientist working at the Princess Alexandra Hospital (PAH) and Queensland University of Technology (QUT) Translational Research Institute (TRI) laboratories on the PAH campus. He is president of the British Thoracic Oncology Group (BTOG), a board member of the European thoracic oncology platform (ETOP), a member of the ESMO chest tumours faculty and is involved in the International Association for the Study of Lung Cancer (IASLC) and Thoracic Alliance for Cancer Trials (TACT). In Australia, he is a member of Australian Lung cancer Trials Group (ALTG), Medical Oncology Group of Australasia (MOGA) and Australian Genomics Health Alliance (AGHA). Prof O'Byrne has been involved in over 150 Clinical Trials in his career including designing investigator-initiated, grant-funded Phase II and III studies. He has established collaborative studies and networks for biomarker detection and validation and has been involved in biomarker driven clinical trials including the LUX-Lung (Boehringer-Ingelheim), checkpoint immunotherapy (BMS,MSD) and the ETOP programs. He is clinical lead for the 'Cancer and Ageing Research Program' at PAH-QUT-TRI, his research including biomarker identification in solid and liquid biopsies, drug resistance linked to cancer 'stemness' and genomic instability. He has published over 300 peer-reviewed manuscripts and has recently patented novel anti-cancer therapeutics (Australian Provisional Patent Number 2015905380). He and his collaborators have successfully applied for NHMRC, CCQ, Prostate Cancer Foundation of Australia (PCFA) and Movember grants in Australia.
Abstracts this author is presenting: